文献速递心力衰竭与心肌病

Vutrisiran改善ATTR淀粉样心肌病生存并减少心血管事件:HELIOS-B

Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B.
PubMed 文献 · J Am Coll Cardiol · 2025-04-30

HELIOS-B随机对照试验纳入655例转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)患者,评估皮下RNA干扰药物Vutrisiran 25 mg每3个月一次对比安慰剂。延长随访至39–42个月显示,Vutrisiran降低全因死亡、心血管死亡、心血管住院、心衰住院及紧急心衰就诊风险。

要点

  • Vutrisiran降低ATTR-CM患者全因死亡风险(HR 0.64;95%CI 0.46-0.88)。
  • Vutrisiran降低心血管死亡、心血管住院与心衰住院风险。
  • 无论基线是否使用tafamidis,趋势一致。

核心结论

  • 在ATTR-CM患者中,Vutrisiran较安慰剂可靠降低全因死亡、心血管死亡、心血管住院、心衰住院和紧急心衰就诊风险。

研究设计与样本

  • HELIOS-B为随机对照试验,655例患者随机接受Vutrisiran 25 mg或安慰剂每3个月一次,双盲期最长33–36个月,随后进入开放标签延长期。
  • 死亡与心血管死亡分析采用随访39–42个月数据(双盲期及开放标签延长期最多6个月);心血管住院与心衰事件评估于33–36个月双盲期。

主要发现

  • 总体人群中,Vutrisiran较安慰剂降低全因死亡风险(HR:0.64;95%CI:0.46-0.88)和心血管死亡风险(HR:0.67;95%CI:0.47-0.96)。
  • Vutrisiran降低心血管死亡与心血管事件复合终点风险(HR:0.72;95%CI:0.55-0.94)。
  • Vutrisiran降低心血管住院率(率比RR:0.75;95%CI:0.62-0.91)、紧急心衰就诊率(RR:0.54;95%CI:0.30-0.98)和心衰住院率(RR:0.67;95%CI:0.52-0.86)。
  • 无论基线是否使用tafamidis,均见一致趋势。

临床怎么用

  • 对ATTR-CM患者,可考虑Vutrisiran 25 mg皮下每3个月一次以降低死亡及心衰事件风险,具体用药需结合适应证与可及性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) have high mortality and morbidity. Vutrisiran, a subcutaneous RNA interference therapeutic, reduced the composite of all-cause mortality (ACM) and cardiovascular (CV) events (CV hospitalizations and urgent heart failure [HF] visits) in HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy) in patients with ATTR-CM. OBJECTIVES: Here we present data from HELIOS-B evaluating the impact of vutrisiran on ACM and CV mortality with additional patient follow-up through 42 months, and CV events such as CV hospitalizations, HF hospitalizations, and urgent HF visits. METHODS: The HELIOS-B trial randomized 655 patients to vutrisiran 25 mg or placebo once every 3 months for up to 33 to 36 months in the double-blind (DB) period, followed by an open-label extension. Prespecified mortality and CV mortality analyses used data through 39 to 42 months of follow-up (DB period and up to 6 months of the open-label extension). CV hospitalizations and HF events were evaluated over the DB period of 33 to 36 months. Differences between vutrisiran and placebo were evaluated in the overall population, and in those stratified by baseline tafamidis use. RESULTS: In the overall population, vutrisiran reduced the risk of ACM (HR: 0.64; 95% CI: 0.46-0.88) and CV mortality (HR: 0.67; 95% CI: 0.47-0.96) vs placebo. Vutrisiran also reduced the risk of a composite of CV mortality and CV events (HR: 0.72; 95% CI: 0.55-0.94), and lowered rates of CV hospitalizations (rate ratio [RR]: 0.75; 95% CI: 0.62-0.91), urgent HF visits (RR: 0.54; 95% CI: 0.30-0.98), and HF hospitalizations (RR: 0.67; 95% CI: 0.52-0.86) vs placebo. Consistent trends were seen regardless of baseline tafamidis use. CONCLUSIONS: Consistent with the primary trial results, vutrisiran reliably reduced the risk of ACM, CV mortality, CV hospitalizations, HF hospitalizations, and urgent HF visits vs placebo in patients with ATTR-CM. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Witteles RM, Garcia-Pavia P, Damy T, et al. Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. J Am Coll Cardiol. 2025. PMID: 40380962. doi:10.1016/j.jacc.2025.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。